Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - Arcturus Therapeutics reported a quarterly loss of $0.34 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.11, representing an earnings surprise of +69.37% [1] - The company posted revenues of $28.3 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 20.84%, although this is a decline from $49.86 million in the same quarter last year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Arcturus Therapeutics shares have declined approximately 29.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Arcturus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.12 on revenues of $20.92 million, and for the current fiscal year, it is -$3.73 on revenues of $70.59 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Arcturus operates, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]